Mmp13, also known as Matrix metalloproteinase-13, is a zinc-dependent endopeptidase that belongs to the matrix metalloproteinase family. It plays a crucial role in degrading extracellular matrix components, especially type II collagen, and is involved in various biological processes such as tissue remodeling, development, and repair. It has been implicated in multiple disease-related pathways, including those related to osteoarthritis, dental caries, and periodontal diseases [1,2,4]. Genetic models, like KO/CKO mouse models, are valuable for studying its function in vivo.

In osteoarthritis (OA), Mmp13 is the primary MMP involved in cartilage degradation, making it an attractive target for OA treatment. Inhibition of Mmp13 in APPswe/PS1E9 mice (an Alzheimer's disease model) reduced BACE1 protein levels, amyloid-β load, and improved learning and memory performances, suggesting its potential role in Alzheimer's disease [1,3]. In a mouse model of deep vein thrombosis (DVT), inhibiting Mmp13 attenuated DVT by reducing the expression of Pdpn, providing a novel gene target for DVT diagnosis and treatment [5].

In conclusion, Mmp13 is essential for extracellular matrix remodeling and is involved in various disease processes. Studies using KO/CKO mouse models have revealed its role in diseases such as osteoarthritis, Alzheimer's disease, and deep vein thrombosis, highlighting its potential as a therapeutic target in these areas.